AstraZeneca prevails in inhaler dispute
AstraZeneca has won a three-year legal battle against UK generics manufacturer Mylan Pharmaceuticals over its asthma inhaler patents.
Five minutes with… Penny Gilbert
The fallout from the landmark Regeneron v Kymab is still being weighed by the UK life sciences community.
WHO head calls for IP waiver to beat COVID-19
The director general of the World Health Organization has called for a waiver on IP rights to ensure more equitable access to COVID-19 vaccines.
A deep dive into Regeneron v Kymab
On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
CPI receives £5m from UK govt for 'vaccine library'
UK innovation hub CPI has received a further £5 million investment from the UK government to support the development of new mRNA vaccines to protect against new variants of COVID-19.
GSK avoids $57m damages award over royalties
GlaxoSmithKline has avoided paying $57 million in damages after a US supreme court reversed a ruling that the pharmaceutical company should not have stopped issuing royalties on a lupus drug.
Senator calls on Biden to reject COVID IP waiver
Thom Tillis, ranking member of the senate IP subcommittee, has urged US president Joe Biden to oppose ‘harmful’ proposals to waive rights related to COVID-19 vaccines currently in discussions at the World Trade Organisation.
Puma and CANBridge cancel licensing deal for $20m
Los Angeles company Puma Biotechnology and Beijing-based CANBridge Pharmaceuticals have cancelled a 2018 licensing deal which gave the latter exclusive rights to a breast cancer drug in China.
India calls for IP waiver to combat COVID-19
The Indian government has called upon members of the WTO to deliver on its proposal to waive IP obligations in order to deal more effectively with the COVID-19 pandemic.
Five minutes with… Eva Kabir
Since the formalisation of the new Biologics Price Competition and Innovation Act (BPCIA) framework in 2014, there has been a wave of patent infringement litigation, leading to a trend of innovator-versus-biosimilar disputes.
